Morepen Laboratories is signaling leadership continuity at the top, with the board announcing the reappointment of Sushil Suri as Chairman and Managing Director for a further three-year term, effective October 20, 2026, subject to approval by shareholders at the company’s 41st AGM. The move follows a presentation of the quarter’s results and other governance matters, underscoring the management’s confidence in a steady hand at the helm as the pharma group pursues its strategic agenda including ongoing organizational changes.
Sushil Suri brings more than three decades of experience in the pharmaceutical sector and is described as a Chartered Accountant and a Fellow member of the Institute of Chartered Accountants of India. His tenure has encompassed strategic and financial planning, manufacturing, capital structuring, and collaborations within the Morepen ecosystem. The announcement also notes that he is a promoter and brother of Sanjay Suri, who serves as Managing Director, highlighting a tightly knit leadership team within the promoter group.
Observers often view such internal reappointments as a signal of governance stability during periods of transformation. While the AGM remains the ultimate venue for investor signals, the board’s move to extend Suri’s leadership for another term points to a preference for continuity as Morepen navigates growth opportunities and the planned restructuring moves surrounding its Medical Devices business.
The 41st AGM is scheduled for September 26, 2026, to be conducted via video conferencing/other audio-visual means, with the reappointment of the Chairman & Managing Director to be considered by members. In the meantime, Morepen continues to advance its quarterly agenda and broader strategic priorities, leaning on experienced leadership to steer the company through a dynamic pharmaceutical landscape.